Clinical trials: Stage II Breast Carcinoma
Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.
- Conditions
- Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00577122
- Testing
- Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
HER2-positive Breast Cancer
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
This is a phase II trial exploring the maintenance therapy with trastuzumab combined with pyrotinib or dalpiciclib and endocrine therapy in HER2-positive advanced breast cancer based on different hormone receptor (HR) statuses…
- Trial name
- NCT07179939
- Testing
- Trastuzumab rezetecan, Pyrotinib, Dalpiciclib
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Fudan University
Breast Cancer, Pain
Chronic Pain in Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Learning about chronic pain in women who have undergone surgery for breast cancer may help improve the quality of life for these patients and may help doctors plan the best treatment.
- Conditions
- Breast Cancer, Pain, Perioperative/Postoperative Complications
- Trial name
- NCT00971919
- Testing
- questionnaire administration, assessment of therapy complications, psychosocial assessment and care
- Where
- United Kingdom
- Volunteers
- 284 people
- Sponsor
- Aberdeen Royal Infirmary
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment
This is a non-significant risk, double-blinded, randomized, registrational study to compare the effectiveness of two digital, software only, medical devices (SaMD) (attune™ and cerena™) in reducing cancer-related anxiety and…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Stage I Lung Cancer AJCC v8
- Trial name
- NCT04862195
- Testing
- Attune™, Cerena™
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- Blue Note Therapeutics
Metastatic Breast Cancer, Hormone Receptor Positive
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
This phase II trial studies the side effects of palbociclib when given together with fulvestrant or tamoxifen citrate in treating patients with hormone receptor positive breast cancer that has spread from where it started to…
- Trial name
- NCT02384239
- Testing
- Palbociclib, Tamoxifen, Fulvestrant
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
HER-2 Positive Breast Cancer
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
The main purpose of this study is to confirm the high pathologic complete response rate after neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Human Epidermal growth factor receptor2…
- Trial name
- NCT01340430
- Testing
- Trastuzumab
- Where
- 6 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Lucia Del Mastro,MD
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
- Trial name
- LoTam (NCT06671912)
- Testing
- Anastrozole, Letrozole, Exemestane
- Where
- 732 sites in United States, Puerto Rico
- Volunteers
- 1,556 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer
The purposes of this study are : to investigate the safety and clinical efficacy of sole therapy with DLBS1425 in suppressing disease-(tumour) progression in subjects with advanced/metastatic breast cancer; and to determine the…
- Trial name
- NCT01006785
- Testing
- DLBS1425
- Where
- 3 sites in Indonesia
- Volunteers
- 15 people
- Sponsor
- Dexa Medica Group
Metastatic Breast Cancer
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
- Trial name
- NCT00303108
- Testing
- Pegylated liposomal doxorubicin, Carboplatin, trastuzumab
- Where
- 57 sites in United States
- Volunteers
- 136 people
- Sponsor
- US Oncology Research
Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
This phase I/II trial study evaluates the tolerability and best tolerated dose of the PI3K inhibitor GDC-0941 when given with the chemotherapy cisplatin.
- Conditions
- Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01918306
- Testing
- cisplatin, laboratory biomarker analysis, pharmacological study
- Where
- 16 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
METASTATIC BREAST CANCER
Ixabepilone and SBRT For Metastatic Breast Cancer
This study is being done to find the effect of Stereotactic body radiation therapy (SBRT) in combination with Ixabepilone for women with triple negative metastatic breast cancer.
- Trial name
- NCT01818999
- Testing
- IXABEPILONE, STEREOTACTIC BODY RADIATION THERAPY
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Breast Cancer
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent breast cancer
- Trial name
- NCT01023204
- Testing
- Paclitaxel
- Volunteers
- 68 people
- Sponsor
- Bristol-Myers Squibb
Locally Recurrent/Metastatic Triple Negative Breast Cancer
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
The study is being done to find out if the results of a pre-treatment biopsy can predict response to cisplatin and radiation treatment for patients with metastatic or recurrent triple negative breast cancer.
- Trial name
- NCT02422498
- Testing
- external beam radiation therapy, cisplatin, Biopsy of Target Tumor
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia
- Trial name
- NCT00293384
- Testing
- Aprepitant, Cyclophosphamide, Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Triple Negative Breast Cancer
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
The purpose of this study is to determine the activity of ENMD-2076 as defined by the clinical benefit rate when patients with previously treated locally advanced or metastatic triple negative breast cancer are treated with daily…
- Trial name
- NCT01639248
- Testing
- ENMD-2076
- Where
- 3 sites in United States, China
- Volunteers
- 41 people
- Sponsor
- CASI pharmaceuticals, Inc.
Breast Cancer
BKM120 For Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) has an aggressive phenotype and poor prognosis. This tumor type characterized by lack of expression of estrogen receptor (ER), progesterone receptor (PR) and no amplification of the human…
- Trial name
- NCT01790932
- Testing
- BKM120
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Hormone Receptor Positive Tumor
Dose EScalation Induction of EvERolimus
The BOLERO-2 study demonstrated a benefit for patients who received everolimus in addition to exemestane in patients who progressed during/after a non-steroidal aromatase inhibitor; Routine use of everolimus shows an high rate of…
- Trial name
- Desiree (NCT02387099)
- Testing
- 3 weeks Dose Induction of Everolimus, 3 weeks Conventional Everolimus Dosing, Open Label Phase with conventional 10mg Everolimus Dosing week 4-24
- Where
- 14 sites in Germany
- Volunteers
- 156 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
The purpose of this study is to determine if BMS-690514 + letrozole will be more effective than lapatinib + letrozole in patients who have metastatic hormone receptor positive breast cancer after developing progressive disease…
- Trial name
- NCT01068704
- Testing
- BMS-690514, Lapatinib, Letrozole
- Where
- 8 sites in United States, Argentina and 2 more
- Volunteers
- 4 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
PET in Breast Cancer Receiving Neoadjuvant Chemotherapy
Prognostic factors in locally advanced breast cancer treated with neoadjuvant chemotherapy differ from those of early breast cancer.
- Trial name
- DA-PET (NCT01396655)
- Testing
- docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)
- Volunteers
- 78 people
- Sponsor
- Seoul National University Hospital
Neoplasms
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
A randomised double blind placebo controlled phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase inhibitor therapy.
- Trial name
- FURVA (NCT02530411)
- Testing
- Fulvestrant, Vandetanib
- Where
- 5 sites in United Kingdom
- Volunteers
- 160 people
- Sponsor
- Velindre NHS Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.